🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery
Pharma is suddenly paying for Bio Ă— AI tools, and Chai is leading the pack with four deals closed this summer. Cofounder Matt McPartlon and Product leader Neil Patil explain why.
Record details
Published: 11 August 2026
Source: Latent Space
Category: Field notes
Topics: Biotech
Retrieved: 12 August 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
🔬Causal Models Need Causal Data - Xaira’s X-Cell model for Drug Discovery (Bo Wang & Ci Chu, Chief Discovery Officer & Chief AI Scientist)
Latent Space · 21 July 2026
How AI and Genomics Are Changing Disease Detection and Precision Medicine
AI for Good (ITU) · 12 August 2026
Corals Spin Tiny Vortices to Get Oxygen, but Not if It’s Too Hot
Quanta Magazine AI · 5 August 2026
đź”® Leopold & exponential markets; transformative GLP-1s; runaway AI & the future of safety++ #595
Exponential View (Azeem Azhar) · 2 August 2026
Scientific computing in the age of agentic AI
OpenAI · 28 July 2026
Can cells think?
Aeon (technology) · 22 July 2026
How to cite this record
ethics.ai (11 August 2026), “🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery,” evidence record 18493, https://ethics.ai/record/18493 (originally published by Latent Space).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.